Bringing the very best science and medicine to our best equine friends
September 11, 2017

Kindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. Sundlof

SAN FRANCISCO, Sept. 11, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Stephen Sundlof will retire in January of 2018 and that, simultaneous with his retirement, Dr. Hangjun Zhanwill be promoted to the position of Chief Scientific Officer. Dr. Zhan has over 20 years of experience in the biotechnology sector and is a world-renowned expert in protein design, expression, production, biochemistry, and biophysics. He holds a B.Sc. degree from Zhejiang University, M.S. and Ph.D. degrees from the University of Washington, and completed a post-doctoral fellowship at Harvard Medical School. Dr. Zhan is also the …

Continue Reading